MDT Medtronic

XNYS Up Alert

Health Care

· How we analyze

About the company

Medtronic is a medical technology company based in Ireland. It makes pacemakers, heart valves, insulin pumps, spinal implants, neurostimulators and surgical instruments. The diabetes division is to be separated. As of Oct 13, 2026

Fact sheet (from the annual report) Electromedical equipment · Galway

Medtronic, based in Galway, Ireland, serves health systems, physicians, clinicians and patients. The Cardiovascular Portfolio, Neuroscience Portfolio and Medical Surgical Portfolio segments develop, manufacture and sell mainly device-based therapies and services. In cardiology, the offering includes pacemakers, products for atrial fibrillation and products for heart valve repair and replacement. Neuroscience comprises navigation and robotic systems for spine and cranial procedures, spinal implants and stroke products. The Medical Surgical Portfolio is aimed mainly at health systems, physician offices and ambulatory surgery centers. In March 2026 the MiniMed diabetes division completed an initial public offering, and in the final quarter of fiscal year 2026 diabetes was no longer a reportable segment.

Automatically summarized from SEC annual report (10-K, filed Jun 18, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −0.9%
  • 7 days −0.7%
  • 30 days +6.0%
  • 1 year −0.2%
Day range (last trading day)
−0.2%Price at 25% of the range+0.6%
52-week range
−22.0%Price at 63% of the range+13.2%
Distance from the all-time high
−30.9%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Double bottom · Analysis method

This method currently detects no pattern for MDT. The check runs daily after the close.

You see new patterns immediately from Watcher, on the free plan 2 days after they form. Plans and pricing

What does the pattern show?

What is this? The price has formed two similarly deep lows and broken above the neckline between them. This is seen as a sign that the downward move is ending.

This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:MDT

Fundamental analysis

Medtronic · Sector Health Care · amounts in USD

Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Jun 18, 2026.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Apr 24, 2026

Quality Profitability, consistency, balance sheet 7 of 8 criteria met Growth Revenue and earnings per share 5 of 7 criteria met Dividend Level, consistency, coverage 6 of 7 criteria met Financial strength Piotroski, debt, liquidity 6 of 6 criteria met

Quality 7 of 8 met

  • met: Gross margin above 40% 65.0%
  • met: Operating margin above 15% 17.8%
  • met: Net margin above 10% 13.2%
  • not met: Return on equity above 15% 9.7%
  • met: Free cash flow margin above 10% 14.9%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 53.2%
Gross margin

65.0% Fiscal year 2026

Rank 72 of 100: higher than 72% of 153 peers (All). strong.

Rank 43 of 100: higher than 43% of 20 peers (Sector). medium.

Median Health Care: 66.6%

Share of revenue left after the direct cost of the products sold.

Operating margin

17.8% Fiscal year 2026

Rank 53 of 100: higher than 53% of 192 peers (All). medium.

Rank 48 of 100: higher than 48% of 20 peers (Sector). medium.

Median Health Care: 18.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

13.2% Fiscal year 2026

Rank 51 of 100: higher than 51% of 237 peers (All). medium.

Rank 48 of 100: higher than 48% of 26 peers (Sector). medium.

Median Health Care: 13.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

9.7% Fiscal year 2026

Rank 31 of 100: higher than 31% of 218 peers (All). weak.

Rank 26 of 100: higher than 26% of 21 peers (Sector). weak.

Median Health Care: 14.3%

Net income divided by equity at fiscal year end.

Return on assets

5.2% Fiscal year 2026 (total assets at year end)

Rank 46 of 100: higher than 46% of 238 peers (All). medium.

Rank 40 of 100: higher than 40% of 26 peers (Sector). medium.

Median Health Care: 6.4%

Net income divided by total assets at fiscal year end.

Equity ratio

53.2% Fiscal year 2026

Rank 73 of 100: higher than 73% of 239 peers (All). strong.

Rank 71 of 100: higher than 71% of 26 peers (Sector). strong.

Median Health Care: 38.5%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

14.9% Fiscal year 2026

Rank 53 of 100: higher than 53% of 213 peers (All). medium.

Rank 50 of 100: higher than 50% of 25 peers (Sector). medium.

Median Health Care: 14.9%

Free cash flow divided by revenue.

Free cash flow

5.4B USD Fiscal year 2026

Operating cash flow minus capital expenditure on property and equipment.

Growth 5 of 7 met

  • met: Over 3 years, revenue grew by more than 5% per year +5.2%
  • not met: Over 5 years, revenue grew by more than 5% per year +3.8%
  • not met: Over 10 years, revenue grew by more than 5% per year +2.3%
  • met: Over 3 years, EPS grew by more than 5% per year +9.8%
  • met: Over 5 years, EPS grew by more than 5% per year +7.0%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 4 of 5
  • met: Revenue rose in the last fiscal year +8.4%
Revenue growth 3 years

+5.2% per year

Rank 37 of 100: higher than 37% of 230 peers (All). medium.

Rank 46 of 100: higher than 46% of 25 peers (Sector). medium.

Median Health Care: +5.6%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+3.8% per year

Rank 15 of 100: higher than 15% of 217 peers (All). weak.

Rank 18 of 100: higher than 18% of 25 peers (Sector). weak.

Median Health Care: +8.5%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+2.3% per year

Rank 19 of 100: higher than 19% of 157 peers (All). weak.

Rank 13 of 100: higher than 13% of 19 peers (Sector). weak.

Median Health Care: +10.1%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+9.8% per year

Rank 45 of 100: higher than 45% of 157 peers (All). medium.

Rank 66 of 100: higher than 66% of 22 peers (Sector). medium.

Median Health Care: +5.5%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+7.0% per year

Rank 28 of 100: higher than 28% of 146 peers (All). weak.

Rank 53 of 100: higher than 53% of 20 peers (Sector). medium.

Median Health Care: +7.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+4.2% per year

Rank 21 of 100: higher than 21% of 140 peers (All). weak.

Rank 33 of 100: higher than 33% of 20 peers (Sector). medium.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 6 of 7 met

  • met: Pays a dividend 2.84 USD
  • not met: Payout ratio at most 60% of earnings 76%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +4.1%
  • met: Free cash flow per share covers the dividend 1.5x
  • met: Dividends paid over the last 5 years covered by free cash flow 68% of free cash flow
Payout ratio

76% Fiscal year 2026

Dividend per share divided by earnings per share.

Dividend growth 5 years

+4.1% per year

Rank 18 of 100: higher than 18% of 118 peers (All). weak.

Rank 9 of 100: higher than 9% of 16 peers (Sector). weak.

Median Health Care: +7.8%

Growth of the dividend per share per year.

Free cash flow coverage

1.5x Fiscal year 2026

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 6 of 6 met

  • met: Piotroski F-Score at least 7 of 9 7 of 9
  • met: Long-term debt no higher than equity 0.53
  • met: Current assets cover current liabilities 2.13
  • met: Positive equity 49.5B USD
  • met: In 5 years, share count up by at most 5% −4.9%
  • met: Free cash flow positive in the last fiscal year 5.4B USD
Piotroski F-Score

7 of 9 Fiscal year 2026

Rank 72 of 100: higher than 72% of 134 peers (All). strong.

Rank 63 of 100: higher than 63% of 19 peers (Sector). medium.

Median Health Care: 7.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.53 at fiscal year end

Rank 55 of 100: lower than 55% of 199 peers (All). medium.

Rank 69 of 100: lower than 69% of 18 peers (Sector). strong.

Median Health Care: 0.72

Long-term financial debt divided by equity.

Liquidity (current ratio)

2.13 at fiscal year end

Rank 70 of 100: higher than 70% of 215 peers (All). strong.

Rank 71 of 100: higher than 71% of 26 peers (Sector). strong.

Median Health Care: 1.56

Current assets divided by current liabilities.

Change in share count

−4.9% in 5 years

Rank 61 of 100: lower than 61% of 199 peers (All). medium.

Rank 56 of 100: lower than 56% of 24 peers (Sector). medium.

Median Health Care: −2.7%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+3.8% per year), more slowly than the sector median.
  • Light yellow: Net income (total) grew over 5 years (+5.9% per year), more slowly than the sector median; per share +7.0% per year.
  • Light green: Net margin 13.2%, above the sector median (12.9%).
  • Light green: Debt not higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.
  • Light yellow: High payout ratio (76% of earnings).

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2017 (Apr 30, 2016 – Apr 28, 2017): Revenue 29.7B USD · Net income 4.0B USD · Net margin 13.6%
  2. Fiscal year 2018 (Apr 29, 2017 – Apr 27, 2018): Revenue 30.0B USD · Net income 3.1B USD · Net margin 10.4%
  3. Fiscal year 2019 (Apr 28, 2018 – Apr 26, 2019): Revenue 30.6B USD · Net income 4.6B USD · Net margin 15.2%
  4. Fiscal year 2020 (Apr 27, 2019 – Apr 24, 2020): Revenue 28.9B USD · Net income 4.8B USD · Net margin 16.6%
  5. Fiscal year 2021 (Apr 25, 2020 – Apr 30, 2021): Revenue 30.1B USD · Net income 3.6B USD · Net margin 12.0%
  6. Fiscal year 2022 (May 1, 2021 – Apr 29, 2022): Revenue 31.7B USD · Net income 5.0B USD · Net margin 15.9%
  7. Fiscal year 2023 (Apr 30, 2022 – Apr 28, 2023): Revenue 31.2B USD · Net income 3.8B USD · Net margin 12.0%
  8. Fiscal year 2024 (Apr 29, 2023 – Apr 26, 2024): Revenue 32.4B USD · Net income 3.7B USD · Net margin 11.4%
  9. Fiscal year 2025 (Apr 27, 2024 – Apr 25, 2025): Revenue 33.5B USD · Net income 4.7B USD · Net margin 13.9%
  10. Fiscal year 2026 (Apr 26, 2025 – Apr 24, 2026): Revenue 36.4B USD · Net income 4.8B USD · Net margin 13.2%

Fiscal year 2026 (Apr 26, 2025 – Apr 24, 2026): Revenue 36.4B USD · Net income 4.8B USD · Net margin 13.2%

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2026

Of 100 USD of revenue, 65.0 USD gross profit, 17.8 USD operating income and 13.2 USD net income remained.

Money flow as a table
Fiscal year 2026, amounts in USD, share of revenue
ItemAmountof revenue
Revenue36.4B USD100.0%
Gross profit23.6B USD65.0%
Cost of revenue12.7B USD35.0%
Operating income6.5B USD17.8%
Research & development2.9B USD7.9%
Other operating expenses14.3B USD39.3%
Net income4.8B USD13.2%
Interest expense715.0M USD2.0%
Taxes & other (net)951.0M USD2.6%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin rose in 5 years from 14.9% to 17.8%.

Gross marginOperating marginNet margin
  1. Fiscal year 2017: Gross margin 68.7% · Operating margin 17.9% · Net margin 13.6%
  2. Fiscal year 2018: Gross margin 69.8% · Operating margin 22.2% · Net margin 10.4%
  3. Fiscal year 2019: Gross margin 70.0% · Operating margin 20.5% · Net margin 15.2%
  4. Fiscal year 2020: Gross margin 67.4% · Operating margin 16.6% · Net margin 16.6%
  5. Fiscal year 2021: Gross margin 65.2% · Operating margin 14.9% · Net margin 12.0%
  6. Fiscal year 2022: Gross margin 68.0% · Operating margin 18.2% · Net margin 15.9%
  7. Fiscal year 2023: Gross margin 65.7% · Operating margin 17.6% · Net margin 12.0%
  8. Fiscal year 2024: Gross margin 65.3% · Operating margin 15.9% · Net margin 11.4%
  9. Fiscal year 2025: Gross margin 65.3% · Operating margin 17.8% · Net margin 13.9%
  10. Fiscal year 2026: Gross margin 65.0% · Operating margin 17.8% · Net margin 13.2%

Returns

Return on equity rose in 5 years from 7.0% to 9.7%.

Return on equityReturn on assets
  1. Fiscal year 2017: Return on equity 8.0% · Return on assets 4.0%
  2. Fiscal year 2018: Return on equity 6.1% · Return on assets 3.4%
  3. Fiscal year 2019: Return on equity 9.2% · Return on assets 5.2%
  4. Fiscal year 2020: Return on equity 9.4% · Return on assets 5.3%
  5. Fiscal year 2021: Return on equity 7.0% · Return on assets 3.9%
  6. Fiscal year 2022: Return on equity 9.6% · Return on assets 5.5%
  7. Fiscal year 2023: Return on equity 7.3% · Return on assets 4.1%
  8. Fiscal year 2024: Return on equity 7.3% · Return on assets 4.1%
  9. Fiscal year 2025: Return on equity 9.7% · Return on assets 5.1%
  10. Fiscal year 2026: Return on equity 9.7% · Return on assets 5.2%

Equity and long-term debt

The equity ratio fell in 5 years from 55.2% to 53.2%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2017: Equity 50.3B USD · Long-term debt 25.9B USD
  2. Fiscal year 2018: Equity 50.7B USD · Long-term debt 23.7B USD
  3. Fiscal year 2019: Equity 50.1B USD · Long-term debt 24.5B USD
  4. Fiscal year 2020: Equity 50.7B USD · Long-term debt 22.0B USD
  5. Fiscal year 2021: Equity 51.4B USD · Long-term debt 26.4B USD
  6. Fiscal year 2022: Equity 52.6B USD · Long-term debt 20.4B USD
  7. Fiscal year 2023: Equity 51.5B USD · Long-term debt 24.3B USD
  8. Fiscal year 2024: Equity 50.2B USD · Long-term debt 23.9B USD
  9. Fiscal year 2025: Equity 48.0B USD · Long-term debt 25.6B USD
  10. Fiscal year 2026: Equity 49.5B USD · Long-term debt 26.2B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 2.65 to 2.13.

Current ratio
  1. Fiscal year 2017: Current ratio 1.75
  2. Fiscal year 2018: Current ratio 2.28
  3. Fiscal year 2019: Current ratio 2.59
  4. Fiscal year 2020: Current ratio 2.13
  5. Fiscal year 2021: Current ratio 2.65
  6. Fiscal year 2022: Current ratio 1.86
  7. Fiscal year 2023: Current ratio 2.39
  8. Fiscal year 2024: Current ratio 2.03
  9. Fiscal year 2025: Current ratio 1.85
  10. Fiscal year 2026: Current ratio 2.13

Cash flow

Free cash flow rose in 5 years from 4.9B USD to 5.4B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2017: Operating cash flow 6.9B USD · Capital expenditure 1.3B USD · Free cash flow 5.6B USD
  2. Fiscal year 2018: Operating cash flow 4.7B USD · Capital expenditure 1.1B USD · Free cash flow 3.6B USD
  3. Fiscal year 2019: Operating cash flow 7.0B USD · Capital expenditure 1.1B USD · Free cash flow 5.9B USD
  4. Fiscal year 2020: Operating cash flow 7.2B USD · Capital expenditure 1.2B USD · Free cash flow 6.0B USD
  5. Fiscal year 2021: Operating cash flow 6.2B USD · Capital expenditure 1.4B USD · Free cash flow 4.9B USD
  6. Fiscal year 2022: Operating cash flow 7.3B USD · Capital expenditure 1.4B USD · Free cash flow 6.0B USD
  7. Fiscal year 2023: Operating cash flow 6.0B USD · Capital expenditure 1.5B USD · Free cash flow 4.6B USD
  8. Fiscal year 2024: Operating cash flow 6.8B USD · Capital expenditure 1.6B USD · Free cash flow 5.2B USD
  9. Fiscal year 2025: Operating cash flow 7.0B USD · Capital expenditure 1.9B USD · Free cash flow 5.2B USD
  10. Fiscal year 2026: Operating cash flow 7.3B USD · Capital expenditure 1.9B USD · Free cash flow 5.4B USD

Share count

The share count fell in 5 years by 4.9% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2017: Diluted share count 1.4B
  2. Fiscal year 2018: Diluted share count 1.4B
  3. Fiscal year 2019: Diluted share count 1.4B
  4. Fiscal year 2020: Diluted share count 1.4B
  5. Fiscal year 2021: Diluted share count 1.4B
  6. Fiscal year 2022: Diluted share count 1.4B
  7. Fiscal year 2023: Diluted share count 1.3B
  8. Fiscal year 2024: Diluted share count 1.3B
  9. Fiscal year 2025: Diluted share count 1.3B
  10. Fiscal year 2026: Diluted share count 1.3B

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
2.84 USD · Fiscal year 2026
Dividend growth per year
3 y +1.4%5 y +4.1%10 y +6.5%
Years without a cut
at least 10 as far as the data goes
Payout ratio
of earnings 76% of free cash flow 67%
To shareholders (5 years)
27.5B USD 35% through repurchases
Share count over 5 years
−4.9% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 2.32 USD to 2.84 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2017: Dividend per share 1.72 USD
  2. Fiscal year 2018: Dividend per share 1.84 USD
  3. Fiscal year 2019: Dividend per share 2.00 USD
  4. Fiscal year 2020: Dividend per share 2.16 USD
  5. Fiscal year 2021: Dividend per share 2.32 USD
  6. Fiscal year 2022: Dividend per share 2.52 USD
  7. Fiscal year 2023: Dividend per share 2.72 USD
  8. Fiscal year 2024: Dividend per share 2.76 USD
  9. Fiscal year 2025: Dividend per share 2.80 USD
  10. Fiscal year 2026: Dividend per share 2.84 USD

Payout ratios

The payout ratio fell in 5 years from 87.2% to 76.1%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2017: Payout ratio (earnings) 59.5% · Payout ratio (free cash flow) 42.2%
  2. Fiscal year 2018: Payout ratio (earnings) 81.1% · Payout ratio (free cash flow) 69.0%
  3. Fiscal year 2019: Payout ratio (earnings) 58.7% · Payout ratio (free cash flow) 45.9%
  4. Fiscal year 2020: Payout ratio (earnings) 61.0% · Payout ratio (free cash flow) 48.1%
  5. Fiscal year 2021: Payout ratio (earnings) 87.2% · Payout ratio (free cash flow) 63.9%
  6. Fiscal year 2022: Payout ratio (earnings) 67.6% · Payout ratio (free cash flow) 56.6%
  7. Fiscal year 2023: Payout ratio (earnings) 96.5% · Payout ratio (free cash flow) 79.0%
  8. Fiscal year 2024: Payout ratio (earnings) 100.0% · Payout ratio (free cash flow) 70.5%
  9. Fiscal year 2025: Payout ratio (earnings) 77.6% · Payout ratio (free cash flow) 69.2%
  10. Fiscal year 2026: Payout ratio (earnings) 76.1% · Payout ratio (free cash flow) 67.1%

What goes back to shareholders

Over 5 years, 27.5B USD went back to shareholders, 35% of it through share repurchases. That is 104% of the free cash flow of those years. This was offset by new shares issued for 1.3B USD (including employee plans).

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2017: Dividends paid 2.4B USD · Share repurchases 3.5B USD · New shares issued (including employee plans) not available · Free cash flow 5.6B USD
  2. Fiscal year 2018: Dividends paid 2.5B USD · Share repurchases 2.2B USD · New shares issued (including employee plans) not available · Free cash flow 3.6B USD
  3. Fiscal year 2019: Dividends paid 2.7B USD · Share repurchases 2.9B USD · New shares issued (including employee plans) not available · Free cash flow 5.9B USD
  4. Fiscal year 2020: Dividends paid 2.9B USD · Share repurchases 1.3B USD · New shares issued (including employee plans) not available · Free cash flow 6.0B USD
  5. Fiscal year 2021: Dividends paid 3.1B USD · Share repurchases 652.0M USD · New shares issued (including employee plans) not available · Free cash flow 4.9B USD
  6. Fiscal year 2022: Dividends paid 3.4B USD · Share repurchases 2.5B USD · New shares issued (including employee plans) not available · Free cash flow 6.0B USD
  7. Fiscal year 2023: Dividends paid 3.6B USD · Share repurchases 645.0M USD · New shares issued (including employee plans) not available · Free cash flow 4.6B USD
  8. Fiscal year 2024: Dividends paid 3.7B USD · Share repurchases 2.1B USD · New shares issued (including employee plans) 284.0M USD · Free cash flow 5.2B USD
  9. Fiscal year 2025: Dividends paid 3.6B USD · Share repurchases 3.2B USD · New shares issued (including employee plans) 508.0M USD · Free cash flow 5.2B USD
  10. Fiscal year 2026: Dividends paid 3.6B USD · Share repurchases 1.0B USD · New shares issued (including employee plans) 516.0M USD · Free cash flow 5.4B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Medtronic next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison MDT, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
ABBV AbbVie 61.2B USD +6.0%70.2%24.6%6.9%–−2.4%29.1%8/9
BMY Bristol Myers Squibb 48.2B USD +2.5%71.1%–14.6%38.2%20.5%26.7%8/9
TMO Thermo Fisher Scientific 44.6B USD +6.7%–17.4%15.0%12.6%48.4%14.1%–
ABT Abbott Laboratories 44.3B USD +5.1%56.4%18.2%14.7%12.5%60.1%16.7%6/9
AMGN Amgen 36.8B USD +7.6%67.2%24.7%21.0%89.1%9.6%22.0%7/9
MDT Medtronic this stock 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
Median of the sector 26 symbols 44.4B USD +8.5%66.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+3.8% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 3.8% per year on average, but more slowly than the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light yellow: below sector

+5.9% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +7.0% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 5.9% per year on average, but more slowly than the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

13.2% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 13.20 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 12.0%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.51 latest balance sheet

Sector Health Care: median 0.66 (49 symbols)

What does this mean? For every 1 USD of equity there is 0.51 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light yellow: high

76% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.76 USD went to shareholders as a dividend. Little buffer remains for weaker years. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
36.4B USD
Revenue vs. prior year
+8.4%
Net income (FY)
4.8B USD
Net income vs. prior year
+3.0%
EPS (FY)
3.73 USD
13F funds with a position
1 of 9
Funds vs. prior quarter
±0
Shares held vs. prior quarter
+1,330.3%
Fiscal year to Apr 24, 2026 · 10-K filed Jun 18, 2026 · Balance sheet Jul 31, 2026 (filed Sep 3, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2026Apr 24, 2026 36.4B4.8B 13.2% 3.73 2.84 76%
2025Apr 25, 2025 33.5B4.7B 13.9% 3.61 2.80 78%
2024Apr 26, 2024 32.4B3.7B 11.4% 2.76 2.76 100%
2023Apr 28, 2023 31.2B3.8B 12.0% 2.82 2.72 96%
2022Apr 29, 2022 31.7B5.0B 15.9% 3.73 2.52 68%
2021Apr 30, 2021 30.1B3.6B 12.0% 2.66 2.32 87%
2020Apr 24, 2020 28.9B4.8B 16.6% 3.54 2.16 61%
2019Apr 26, 2019 30.6B4.6B 15.2% 3.41 2.00 59%
2018Apr 27, 2018 30.0B3.1B 10.4% 2.27 1.84 81%
2017Apr 28, 2017 29.7B4.0B 13.6% 2.89 1.72 60%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Jul 31, 2026 9.8B1.5B 15.1% 1.14 0.72 63%
Q2/26*Apr 24, 2026 9.8B1.2B 12.7% – – –
Q1/26Jan 23, 2026 9.0B1.1B 12.7% 0.89 0.71 80%
Q4/25Oct 24, 2025 9.0B1.4B 15.3% 1.07 0.71 66%
Q3/25Jul 25, 2025 8.6B1.0B 12.1% 0.81 0.71 88%
Q2/25*Apr 25, 2025 8.9B1.1B 11.8% – – –
Q1/25Jan 24, 2025 8.3B1.3B 15.6% 1.01 0.70 69%
Q4/24Oct 25, 2024 8.4B1.3B 15.1% 0.99 0.70 71%
Q3/24Jul 26, 2024 7.9B1.0B 13.2% 0.80 0.70 88%
Q2/24*Apr 26, 2024 8.6B654.0M 7.6% – – –
Q1/24Jan 26, 2024 8.1B1.3B 16.3% 0.99 0.69 70%
Q4/23Oct 27, 2023 8.0B909.0M 11.4% 0.68 0.69 101%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $5.9M3 people −$5.9M
6 months $00 people $6.5M4 people −$6.5M
12 months $00 people $14.7M5 people −$14.7M

Latest transactions

  • Oct 15, 2026 Marinaro Michael Officer Open-market sale · 10b5-1 plan 10,420 shares · $1.0M · SEC
  • Oct 15, 2026 Martha Geoffrey Chief executive (CEO), Director Open-market sale · 10b5-1 plan 50,000 shares · $4.8M · SEC
  • Sep 16, 2026 Kiil Harry Skip Officer Open-market sale 1,483 shares · $138.9K · SEC
  • Jul 8, 2026 Walter Matthew R. Officer Open-market sale · 10b5-1 plan 3,102 shares · $257.9K · SEC
  • Jun 8, 2026 Kiil Harry Skip Officer Open-market sale 228 shares · $18.3K · SEC
  • Jun 8, 2026 Kiil Harry Skip Officer Open-market sale 3,961 shares · $318.6K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +65

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows+0
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)20.8
Rel. strength 60 d+7.3%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on MDT yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: MDT

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close